Is LEGN a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on CARVYKTI commercial ramp, with revenue (ttm, collaboration/license) at ~$1.1B. The bear case rests on legend's value is heavily concentrated in one product, CARVYKTI, and in one partner, Johnson & Johnson, which shares profits and controls much of the commercial engine. Analysts covering it are spread from $27.00 to $80.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Legend's value is heavily concentrated in one product, CARVYKTI, and in one partner, Johnson & Johnson, which shares profits and controls much of the commercial engine. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $27.00, +43.5% from the $18.81 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

CARVYKTI commercial ramp. CARVYKTI net trade sales reached about $1.9 billion in 2025 and rose roughly 62 percent year over year in Q1 2026, with ex-US sales growing far faster than US sales off a smaller base. The most optimistic analyst target on LEGN is $80.00, +325.3% from the $18.81 price. That figure is only reachable if this thesis works close to its best case.

Legend's value is heavily concentrated in one product, CARVYKTI, and in one partner, Johnson & Johnson, which shares profits and controls much of the commercial engine. The multiple-myeloma market is increasingly crowded, with competing CAR-T therapies like Bristol Myers Squibb's Abecma and off-the-shelf BCMA bispecific antibodies such as J&J's Tecvayli and Pfizer's Elrexfio that avoid CAR-T's manufacturing and logistics burden. CAR-T therapies also carry serious safety considerations and manufacturing and capacity constraints that can cap growth. The company is only near breakeven and still posts losses, so any sales miss, pricing pressure, or safety signal can move the stock sharply. As a China-founded, US-listed ADR, it also carries geopolitical, supply-chain, and regulatory exposure that pure-play US biotechs do not. The most pessimistic published target is $27.00, +43.5% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Legend Biotech is a global cell-therapy company best known for CARVYKTI (ciltacabtagene autoleucel, or cilta-cel), a one-time BCMA-directed CAR-T treatment for relapsed or refracto

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (CARVYKTI commercial ramp) stalling in the reported numbers rather than in the narrative, the risk above (legend's value is heavily concentrated in one product, CARVYKTI, and in one partner, Johnson & Johnson, which shares profits and controls much of the commercial engine) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

Legend Biotech is a cell-therapy company whose flagship product is CARVYKTI, a one-time BCMA-directed CAR-T treatment for relapsed or refractory multiple myeloma. It co-develops and shares profits on CARVYKTI with Johnson & Johnson and runs an earlier-stage pipeline of other cell therapies.

Yes. Legend Biotech trades on the Nasdaq under the ticker LEGN as an American Depositary Receipt. The company was founded in China and is legally domiciled outside the US, which adds ADR and geopolitical considerations for investors.

CARVYKTI (cilta-cel) is a personalized CAR-T therapy that reengineers a patient's own T cells to attack BCMA-expressing myeloma cells. It generated roughly $1.9 billion in global net trade sales in 2025 and is essentially the entire commercial story, so its trajectory drives the stock.